Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brain Cancer
New research on brain cancer from Brain Tumor Center summarized
January 28th, 2009
"High-grade astrocytoma (HGA) is an invariably fatal malignancy with a mean survival of 14 months despite surgery, radiation, and chemotherapy. We have found that a restricted receptor for interleukin-13 (IL-13), IL-13 receptor alpha 2 (IL13R alpha 2), is abundantly overexpressed in the vast majority of HGAs but is not appreciably expressed in normal tissue, with the exception of the testes," scientists writing in the journal Cancer Biotherapy and Radiopharmaceuticals report. "Therefore, IL-13R alpha 2 is a very attractive target for anti-HGA immunotherapy. In order to test protein and genetic vaccines that target IL13R alpha 2, we developed a G26-IL13R alpha...
Source: Vaccine Weekly (2009-01-28)
|
